Free tool
FAERS Monitor: Ecoza
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205175 or its brand name (Ecoza, Econazole Nitrate). Reports on generic versions are filed under their own applications.
Reports
947
Serious
615
65% of reports
Hospitalization
335
Death reported
57
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue63
- drug ineffective59
- rash50
- dyspnoea48
- nausea48
- pain47
- diarrhoea45
- dizziness41
- asthenia39
- headache39
- pruritus39
- renal failure38
- anxiety36
- drug interaction34
- fall34
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 9 |
| 2006 | 13 |
| 2007 | 19 |
| 2008 | 21 |
| 2009 | 28 |
| 2010 | 18 |
| 2011 | 34 |
| 2012 | 33 |
| 2013 | 35 |
| 2014 | 15 |
| 2015 | 62 |
| 2016 | 64 |
| 2017 | 74 |
| 2018 | 79 |
| 2019 | 64 |
| 2020 | 73 |
| 2021 | 48 |
| 2022 | 40 |
| 2023 | 53 |
| 2024 | 49 |
| 2025 | 57 |
| 2026 | 51 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,212 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| renal failureSignal | 38 | 6.4 | 4.7 | 167 |
| drug interactionSignal | 34 | 4.8 | 3.4 | 98 |
| anxietySignal | 36 | 2.8 | 2.0 | 41 |
| rashSignal | 50 | 2.5 | 1.9 | 46 |
| astheniaSignal | 39 | 2.3 | 1.7 | 28 |
| fallSignal | 34 | 2.3 | 1.6 | 23 |
| pruritusSignal | 39 | 2.3 | 1.7 | 26 |
| dyspnoea | 48 | 1.9 | 1.4 | 20 |
| dizziness | 41 | 1.8 | 1.4 | 15 |
| fatigue | 63 | 1.8 | 1.4 | 22 |
| pain | 47 | 1.7 | 1.3 | 13 |
| diarrhoea | 45 | 1.5 | 1.2 | 8 |
| headache | 39 | 1.4 | 1.0 | 4 |
| nausea | 48 | 1.3 | 1.0 | 4 |
| drug ineffective | 59 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.